Tell your U.S. senators: Stop the prescription drug patent abuse that's making our medicines unaffordable

The patent system belongs to the American people and exists for our benefit. It's been critical to spurring valuable innovation in medicine -- but unfortunately there exist a number of loopholes that drug companies use to maintain monopoly prices for their drugs.

Take Humira, Abbvie's brand-name drug to treat rheumatoid arthritis, for example: Humira cost $523 per month in 2002. In 2023, it costs $3,167 per month.

Over the next few weeks, the U.S. Senate will be voting on measures to end drug patent abuse tactics. You can make a difference right now by sending an urgent message to the Senate in support of strong federal-level reforms to the patent system.

Subject: Support drug patent reform bills to stop monopoly pricing of Americans' prescription medicines